Novo Nordisk Achieves Primary Endpoint in STEP Young Phase 3 Trial for Pediatric Semaglutide Indication

Positive phase 3 data from Novo Nordisk's STEP Young trial positions semaglutide as a candidate for a new pediatric label covering children aged 6 to under 12, a development that carries direct implications for regulatory submissions, age-appropriate formulation review, and fill-finish capacity planning at commercial scale.

The trial met its primary endpoint: once-weekly subcutaneous semaglutide, combined with lifestyle modification, delivered superior BMI reduction at week 68 versus placebo. Notably, 40.4% of semaglutide-treated children were no longer classified as having obesity at week 68, compared with 0% in the placebo arm. At baseline, more than 85% of enrolled children presented with class II or III severe obesity, making the magnitude of response clinically significant for a population with few approved pharmacological options.

For regulatory affairs leads, the safety profile is a material data point. Novo Nordisk reported that tolerability in STEP Young was consistent with findings from prior adult and adolescent semaglutide trials, with no new safety signals identified. That alignment with the established GLP-1 receptor agonist safety dataset should support a pediatric supplemental NDA or equivalent submission under 21 CFR Part 314, though labeling negotiations for a younger age cohort will require granular pharmacokinetic and dosing justification specific to this population.

Plant heads and supply chain leads should read the STEP Young results against existing Ozempic and Wegovy manufacturing constraints. A new pediatric indication, if approved, would expand the eligible treatment population to an estimated 177 million children aged 5 to 19 living with obesity globally in 2025, a figure projected to reach 228 million by 2040. Incremental demand at that scale requires early-stage capacity modelling, particularly for subcutaneous delivery device components and sterile fill-finish lines already under pressure from adult GLP-1 demand.

The consistency of the safety profile across age groups reduces one regulatory risk variable, but a pediatric-specific label will still require Novo Nordisk to satisfy ICH E11 requirements for clinical investigation in pediatric populations, including age-stratified safety data and, potentially, a pediatric investigation plan assessment in the EU.

Full STEP Young data are expected to be submitted for peer-reviewed publication and presented at a forthcoming scientific congress, with a regulatory filing timeline not yet disclosed; that submission date will be the next measurable checkpoint for QA and regulatory teams tracking this program.

Source: Novo Nordisk via GlobeNewswire, 7 September 2026.